Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Drug Targeting Therapy in Multiple Myeloma
share announcement

Drug Targeting Therapy in Multiple Myeloma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 20 March 2026 | Viewed by 3199

Special Issue Editors

Dr. Hiroshi Handa

E-Mail Website
Guest Editor
Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan
Interests: multiple myeloma; non-coding RNA
Prof. Dr. Hideto Tamura

E-Mail Website
Co-Guest Editor
1. Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Minamikoshigaya, Koshigaya-shi 343-8555, Saitama, Japan
2. Division of Hematology, Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-0086, Japan
Interests: multiple myeloma; tumor microenvironment; tumor immunity; immunotherapy; immune checkpoint
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The prognosis of multiple myeloma has markedly improved due to the development and clinical use of novel agents, such as proteasome inhibitors, cereblon modulators, and antibodies, including anti-CD38 and anti-SLAMF7. However, it is still an incurable malignancy. Eventually, the disease will become resistant to all drugs; therefore, we must identify new therapeutic targets and develop new drugs. Several new therapeutic approaches, including bispecific antibodies connecting CD3+ T cells to the B cell maturation antigen (BCMA) or GPRC5D on myeloma cells, antibody drug conjugates (ADC), and chimeric antigen receptor T cell (CAR-T) therapy, are currently being developed. As the bcl-2 inhibitor, venetoclax, demonstrated good efficacy only against myeloma with t(11;14), developing drugs that target a specific type of myeloma is also a popular topic. Although some myeloma patients now live longer, myeloma has poor prognostic factors, such as adverse cytogenetics, extramedullary disease, and plasma cell leukemia. This Special Issue will cover not only new drugs and their targets, but also new therapeutic targets undergoing basic research exploration.

Dr. Hiroshi Handa
Prof. Dr. Hideto Tamura
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • novel drug
  • novel targets
  • new therapeutic targets
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 7006 KiB  
Article
Role of Rac1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma
by Ikuko Matsumura, Tsukasa Oda, Tetsuhiro Kasamatsu, Yuki Murakami, Rei Ishihara, Ayane Ohmori, Akira Matsumoto, Nanami Gotoh, Nobuhiko Kobayashi, Yuri Miyazawa, Yoshiyuki Ogawa, Akihiko Yokohama, Nobuo Sasaki, Takayuki Saitoh and Hiroshi Handa
Cancers 2025, 17(3), 461; https://doi.org/10.3390/cancers17030461 - 29 Jan 2025
Viewed by 708
Abstract
In this work, the study presented in [...] Full article
(This article belongs to the Special Issue Drug Targeting Therapy in Multiple Myeloma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 881 KiB  
Review
The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
by Carmen Besliu, Alina Daniela Tanase, Ionela Rotaru, Jose Espinoza, Laura Vidal, Martine Poelman, Manel Juan, Carlos Fernández de Larrea and Kamal S. Saini
Cancers 2025, 17(3), 525; https://doi.org/10.3390/cancers17030525 - 5 Feb 2025
Viewed by 2005
Abstract
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial diagnosis being 66 years. In 1975, Durie and Salmon developed the first broadly adopted staging system in multiple [...] Read more.
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial diagnosis being 66 years. In 1975, Durie and Salmon developed the first broadly adopted staging system in multiple myeloma, and in the ensuing decades, the risk stratification tools have improved and now incorporate different parameters to better predict the prognosis and to guide the treatment decisions. The International Staging System (ISS) was initially developed in 2005, revised in 2015 (R-ISS), and again in 2022 (R2-ISS). Tremendous progress has been achieved in multiple myeloma therapy over the past 25 years with the approval of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, resulting in a major paradigm shift. The dysfunction of the innate and adaptive immune system, especially in the T cell repertoire, represents a hallmark of multiple myeloma evolution over time, supporting the need for additional therapeutic approaches to activate the host’s immune system and to overcome the immunosuppressive tumor microenvironment. Novel T cell-directed therapies include chimeric antigen receptor (CAR) T cell therapies and bispecific antibodies that leverage the immune system’s T cells to recognize and attack the tumor cells. Second-generation anti-BCMA CAR T cell therapies and bispecific antibodies that bind the tumor antigen BCMA or GPRC5D onto myeloma cells and CD3 on the T cell’s surface are currently available for the treatment of relapsed/refractory multiple myeloma. Despite impressive results obtained with currently approved treatments, multiple myeloma remains incurable, and almost all patients eventually relapse. Moreover, patients with extramedullary disease and plasma cell leukemia represent an unmet medical need that require additional strategies to improve the outcome. In this review, we provide an overview of the evolution of risk stratification and the treatment of multiple myeloma. Full article
(This article belongs to the Special Issue Drug Targeting Therapy in Multiple Myeloma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop